These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 15056131)

  • 1. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy.
    Lo MK; Lee KF; Chan NN; Leung WY; Ko GT; Chan WB; So WY; Ng MC; Ho CS; Tam JS; Lam CW; Tong PC; Chan JC
    Diabetes Obes Metab; 2004 May; 6(3):223-30. PubMed ID: 15056131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
    Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.
    Parving HH; Mogensen CE; Thomas MC; Brenner BM; Cooper ME
    QJM; 2005 Feb; 98(2):119-26. PubMed ID: 15655096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy.
    Leung WY; So WY; Tong PC; Chan NN; Chan JC
    Am J Med; 2005 Dec; 118(12):1414. PubMed ID: 16378791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicobacter pylori infection in type 2 diabetic patients.
    Quadri R; Rossi C; Catalfamo E; Masoero G; Lombardo L; Della Monica P; Rovera L; Pera A; Cavello Perin P
    Nutr Metab Cardiovasc Dis; 2000 Oct; 10(5):263-6. PubMed ID: 11213535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant macro and microvascular complications in diabetic nephropathy.
    Alwakeel JS; Al-Suwaida A; Isnani AC; Al-Harbi A; Alam A
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):402-9. PubMed ID: 19414942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF; Lyle PA;
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospective follow-up study of renal function in type 2 diabetes].
    Hadjadj S; Fanelli A; Torremocha F; Maréchaud R
    Arch Mal Coeur Vaiss; 2001 Aug; 94(8):928-32. PubMed ID: 11575233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.
    Keane WF; Zhang Z; Lyle PA; Cooper ME; de Zeeuw D; Grunfeld JP; Lash JP; McGill JB; Mitch WE; Remuzzi G; Shahinfar S; Snapinn SM; Toto R; Brenner BM;
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):761-7. PubMed ID: 17699284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
    Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC
    Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
    Jafar TH; Schmid CH; Stark PC; Toto R; Remuzzi G; Ruggenenti P; Marcantoni C; Becker G; Shahinfar S; De Jong PE; De Zeeuw D; Kamper AL; Strangaard S; Levey AS
    Nephrol Dial Transplant; 2003 Oct; 18(10):2047-53. PubMed ID: 13679479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study.
    Bellomo G; Lippi G; Saronio P; Reboldi G; Verdura C; Timio F; Timio M
    J Nephrol; 2003; 16(2):245-51. PubMed ID: 12768072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design.
    Shikata K; Haneda M; Koya D; Suzuki Y; Tomino Y; Yamada K; Maeda S; Kawakami N; Uzu T; Nishimura M; Sato C; Ogawa D; Makino H;
    Diabetes Res Clin Pract; 2010 Feb; 87(2):228-32. PubMed ID: 19889469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B; Gleim G; Panish J
    Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.